Roberto Contieri

❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES! 👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment Full paper➡️euoncology.europeanurology.com/article/S2588-… @EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA

Roberto Contieri Shares Key Insights on Bladder Cancer Care at EAU 2026 @RobertoContieri oncodaily.com/voices/roberto… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter

@tonivilaseca presenting promising early data for intravesical erdafitinib (Erda-iDRS) “TAR 210” in NMIBC presented at #EAU26 ➡️ 83% 12-mo RFS as adjuvant therapy in HR NMIBC (n=26) ➡️ 89% CR at 6 months in IR NMIBC ablative cohort Targeted #FGFR therapy moving earlier into NMIBC disease states. @JoshMeeks @DrFelixGuerrero @IBCG_BladderCA @BladderCancerUS

Which #NMIBC patients may safely receive de-intensified treatment? At #EAU26 @RobertoContieri (@istitutotumori) discusses risk stratification for de-escalation, findings from the ROBUUST database on histological subtypes, and optimizing mitomycin C maintenance in intermediate-risk Ta disease @Uroweb #GUsm #BladderCancer

State-of-the-art lecture treatment de-intensification in #NMIBC. Presentation by @RobertoContieri @IstTumori. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4sgk02k @Uroweb

#EAU26 @RobertoContieri “Less is more” in select NMIBC 🔹 Office-based fulguration 🔹 Active surveillance 🔹 Chemoablation 🎯 The key is patient selection. @uroweb @UroToday

Excellent case for de-escalating management of LGTa #bladdercancer by @RobertoContieri LG Ta has low progression risk & negligible CSM yet… We overtreat LGTa We oversurveil LGTa Active surveillance in well selected pts is safe, cost-effective & maintains excellent QoL #EAU26

Day 2 #EAU26 morning session jam packed with urothelial carcinoma updated and pro/con.. see everyone there ! @MRoupret Laura Mertens @tbivala1 @spsutkaMD @RobertoContieri @tompowles1

Standing room only … but there are some seats open in the front; come on in! ☄️ Rapid Fire Debates: common problems and controversies in #BladderCancer ; 9th Edition Orange Area eURO 2: #EAU26 @ParamMariappan @LAUrology_NL @achoud72 @MRoupret @jteoh_hk @paolo_gontero @BenjaminPradere @BogdanaSchmidt @MattGalsky @NehaVapiwala @tompowles1 #UroTwitter @MaartenAlbersen

Niyati and Nik – thank you for hosting such a wonderful dinner and for the warm hospitality. A truly perfect start to #EAU26. Grateful to everyone who came out to celebrate and spend time together @niyatilobo @nikhilvasdevuro @AlisonBirtle @ParamMariappan @RobertoContieri @drtanws @jteoh_hk

Initial case series and perioperative outcomes of single-port robotic radical prostatectomy: the Italian experience techscience.com/CJU/v33n1/6644… This study reports the first European case series of single-port robot-assisted radical prostatectomy (SP-RARP) using the Da Vinci SP system at the Istituto Nazionale Tumori di Napoli. Sixteen patients underwent extraperitoneal SP-RARP with no conversions or complications. Median console time was 110 minutes and median blood loss 175 cc, with discharge on postoperative day one. The findings demonstrate feasibility for experienced robotic surgeons, though larger studies are needed to assess long-term oncologic and functional outcomes. #ProstateCancer @PandolfoSD @robertocontieri

Looking forward to attending one of the most thought-provoking sessions of #EAU26. "Bladder Cancer rapide fire debate" is always a valuable opportunity for high-level discussion and fresh perspectives in our field.

Featured topics include: TMT for MIBC: Radiation, responsibility, and recurrences – who manages the fallout, and how? @ParamMariappan @NehaVapiwala Urinary markers vs. Cystoscopy: Is it finally time to ditch the scope? @jteoh_hk @paolo_gontero @LAUrology_NL High-risk NMIBC: Is BCG + IO the new standard or overkill? Bladder Preservation: Assessing the data-driven strategy vs. the clinical risk. @BenjaminPradere @BogdanaSchmidt MIBC Systemic Therapy: Maximizing early treatment vs. risk-adapted post-op strategies. @tompowles1 @giannatempopatr @MattGalsky

🚨 Save the Date! 🚨 📢 Join us for the 7th edition of UroNews – International Meeting on April 23-24, 2026 in Naples. Discover the latest in diagnosis and treatment of genitourinary cancers with top experts. 🔗 Register now at uronewsita.it – don’t miss out!

New IBCG consensus: Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group (IBCG) Full text: authors.elsevier.com/a/1mf5C_6tuO0S… @shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery

@drtanws @UroDocAsh Well deserved!

I’m truly honoured to receive the 2026 Hunterian Professorship from the Royal College of Surgeons of England for my work on non-muscle invasive bladder cancer. I owe a debt of gratitude to my mentors John Kelly & @UroDocAsh whose wisdom and encouragement have shaped my journey.

It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs. This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT. And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT. Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression. If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics. This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26 @UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi

SYNERGY 2026 – Second Edition Save the Date: 🗓️ May 28–29, 2026 📍 Naples, Italy 👉 This year’s scientific program will focus on locally advanced and oligometastatic GU tumors, in an integrated MDT setting

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial euoncology.europeanurology.com/article/S2588-… The prospective multicenter HuNIRe trial evaluated a response-guided strategy for second transurethral resection (ReTUR) in T1 non–muscle-invasive bladder cancer. Among 90 patients, 71% safely avoided routine ReTUR after complete initial resection, proceeding directly to BCG therapy. At 2⃣ years, recurrence-free and progression-free survival were 69% and 91%, with no significant differences versus selective or routine ReTUR cohorts. This tailored approach reduced overtreatment without compromising short-term oncological outcomes. #BladderCancer @RobertoContieri @Marco_Paciotti_ @UleriAlessandro @SedighOmid_ @EdoardoBeatrici @ppavolio_MD @FregoNicola @ludovicacella @NBuffi @GLughezzani @OncoAlert 🚨

@Urodoc46 @EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA Great point! "CUT-less" RCT will probably answers to this question @f_delgiudice

@RobertoContieri @EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA Excellent paper! I do wonder how pre-resection MRI bladder can play into this.

❓️Can we avoid ReTURBT in selected patients with T1 NMIBC? ✅️ According to our study YES! 👥️A response-based approach can spare up to 71% of ReTURBT reducing overtreatment Full paper➡️euoncology.europeanurology.com/article/S2588-… @EurUrolOncol @urotoday @Uroweb @oncodaily @IBCG_BladderCA